etectRx Revenue and Competitors

Location

N/A

Total Funding

Event Tech

Industry

Estimated Revenue & Valuation

  • etectRx's estimated annual revenue is currently $1.3M per year.(i)
  • etectRx's estimated revenue per employee is $84,000

Employee Data

  • etectRx has 16 Employees.(i)
  • etectRx grew their employee count by 7% last year.

etectRx's People

NameTitleEmail/Phone
1
VP, Product Management & Regulatory AffairsReveal Email/Phone
2
VP Research & Development at etectRxReveal Email/Phone
3
Director, Integrated Circuit DesignReveal Email/Phone
4
Director Hardware EngineeringReveal Email/Phone
5
Director Technical OperationsReveal Email/Phone
6
Marketing DirectorReveal Email/Phone
7
Project ManagerReveal Email/Phone
8
President, CEOReveal Email/Phone
9
President and CEOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$35.9M2337%N/AN/A
#2
$1.5M186%N/AN/A
#3
$0.3M4-56%N/AN/A
#4
$1.3M167%N/AN/A
#5
$2.3M2321%N/AN/A
Add Company

What Is etectRx?

etectRxâ„¢, Inc. is a Digital Health company that has developed a patented ingestible event marker (the ID-Capâ„¢ System) that provides real-time, dose-level ingestion event verification. The ID-Cap System can be used by patients, healthcare providers, health systems, payers, and research organizations to track ingestion events and to measure, monitor and improve medication adherence and can also be used by pharmaceutical companies to develop Digital Medicine. The ID-Cap System is a medical device that has been cleared by the FDA as an ingestible event marker. The ID-Cap System utilizes a proprietary in vivo communications technology that emits a very low power radio frequency (RF) digital message from within the patient after a sensor is ingested and detects the signal using a wearable Reader. The ID-Cap System is comprised of the ID-Capsule which contains the ingestible sensor (the ID-Tag), the wearable ID-Cap Reader, and related software which allows data to be displayed for the patient and clinician. etectRx has successfully completed 14 IRB-approved clinical trials, including three NIH-sponsored trials, demonstrating the feasibility, effectiveness, and safety of the device in over 5,100 ingestions and 257 study participants.

keywords:N/A

N/A

Total Funding

16

Number of Employees

$1.3M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

etectRx News

2022-04-20 - Global Smart Pills Market Forecast Report 2021-2028 ...

For instance, in January 2021, etectRx, Inc. entered into a partnership agreement with Pear Therapeutics, Inc. to develop two product...

2022-04-17 - Smart Pills Drug Delivery Market to record 16.97% YOY ...

CapsoVision Inc., Check-Cap Ltd., etectRx, General Electric Co., HQ Inc, Insulet Corp., IntroMedic Co. Ltd., Jinshan Science and Technology...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M1623%N/A
#2
$1.4M16220%N/A
#3
$1.3M176%$5M
#4
$1.5M170%N/A
#5
N/A17-26%N/A